Compare Nuwellis Inc (NUWE) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while ProShares UltraPro Short QQQ ETF trades at $32.95 (market cap $2.23B). The key difference: ProShares UltraPro Short QQQ ETF is far larger — about 1013.6× Nuwellis Inc's market cap, and Nuwellis Inc is more actively traded (121,544 versus 60,436,012). Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and ProShares UltraPro Short QQQ ETF for 12 Days on average.
| NUWE | SQQQ | |
|---|---|---|
Market Cap | $2.20M | $2.23B |
Volume | 121,544 | 60,436,012 |
Sector | Health | Leveraged / Inverse |
52-Week High | $146.65 | $89.43 |
52-Week Low | $0.68 | $31.83 |
Typical Hold Time | 26 Days | 12 Days |
Enterprise Value | -$1.52M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
SQQQ (ProShares UltraPro Short QQQ) trades at $33.37, up 4.02% today, reflecting its bearish positioning against the Nasdaq 100. Technical indicators show a predominantly bearish signal with moving averages indicating selling pressure, while oscillators remain neutral. The ETF serves as a leveraged short tool for hedging QQQ exposure, with recent news highlighting its strategic use in portfolio protection amid tech sector volatility.
The outlook for SQQQ remains tied to Nasdaq 100 performance, offering potential gains during market downturns but carrying high risk due to daily rebalancing and decay. Key risks include rapid market reversals and the structural challenges of leveraged inverse ETFs. Investor sentiment is cautious, with media coverage emphasizing its role as a hedging instrument rather than a long-term hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
